STERIS plc (STE): Q4 Earnings Preview and What Investors Should Watch
Key Takeaways
- Analysts expect Q4 fiscal 2026 revenue of approximately $1.60 billion, up about 8% year-over-year.
- Consensus adjusted EPS estimate stands at $2.89, reflecting 5.5% growth from $2.74 in the prior-year quarter.
- STERIS reaffirmed fiscal 2026 guidance for 8-9% revenue growth and adjusted EPS of $10.15-$10.30, factoring in tariff impacts.
- Q3 results showed 9% revenue growth to $1.50 billion and adjusted EPS of $2.53, meeting expectations amid tariff headwinds.
- Investors will focus on segment performance in Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.
- Historical post-earnings moves have been mixed, with positive reactions about 53% of the time over five years.
Earnings Context and Why It Matters
As STERIS plc (STE) wraps up its fiscal 2026 with this Q4 report—covering the quarter ended March 31, 2026—I'm keeping a close eye on how the company navigates ongoing demand for infection prevention and sterilization solutions in healthcare. STERIS reports on a fiscal calendar ending June 30 for Q1, September 30 for Q2, December 31 for Q3, and March 31 for Q4. From what I see, revenue growth has been fueled by volume increases, pricing actions, and strategic acquisitions, making this release pivotal for confirming guidance against an estimated $55 million pre-tax tariff hit. In my view, investors like us need to assess margin resilience here, especially with supply chain pressures and the gradual recovery in procedural volumes shaping valuations across the medical devices sector.
Earnings Expectations
Looking at the numbers, analysts are forecasting Q4 revenue of around $1.60 billion, marking roughly 8% growth from $1.48 billion a year ago. This fits squarely with the company's guidance for full-year 8-9% as-reported growth and 7-8% constant currency organic growth. The consensus adjusted EPS comes in at $2.89, a 5.5% rise from $2.74 in Q4 FY2025, which supports the full-year outlook of $10.15-$10.30 even with tariff pressures. One thing that stands out are the key metrics: procedure volumes in the Healthcare segment, utilization rates at Applied Sterilization Technologies (AST) for end-of-line medical device processing, and demand for consumables in Life Sciences.
For context, Q3 FY2026 (ended December 31, 2025) delivered $1.50 billion in revenue, up 9% year-over-year with 8% constant currency organic growth, and adjusted EPS of $2.53 that met expectations. Historically, STE has seen mixed post-earnings reactions—positive about 53% of the time over the past five years, with median gains of 6% on those up days. I also checked this using Tickeron’s AI Screener to gauge how the stock stacks up against peers on technical patterns and fundamentals leading into this report.
Market Reaction and Investor Sentiment
Sentiment heading into earnings feels cautiously optimistic to me. Shares of STE are down about 3% recently, trading around $207 amid broader market headwinds. Analysts hold a "Moderate Buy" rating, with price targets in the $275-$287 range that suggest roughly 30% upside potential. That said, risks like tariff costs exceeding $55 million or softer procedure volumes loom large; on the flip side, beats on guidance could trigger rallies, given those historical 6% median positive moves.
Forward Outlook and Key Factors to Monitor
Entering fiscal 2027, STERIS carries momentum from steady organic growth, but I'll be tracking how full-year results stack up against guidance. Confirming 8-9% revenue expansion and EPS around the $10.25 midpoint will be crucial, particularly as tariffs squeeze margins.
Key areas to watch include recovery in the Healthcare segment as elective procedures stabilize, AST capacity expansions to handle rising device sterilization needs, and ongoing strength in Life Sciences from biopharma consumables. Updates on tariff mitigation strategies, supply chain costs, and currency impacts—assumed neutral—will matter too.
Longer term, M&A activity and guided free cash flow of $850 million should continue supporting dividends and buybacks. The post-COVID emphasis on infection control strengthens STERIS's positioning, though hospital capital spending and competitive pressures deserve monitoring.
Why I Rely on Tickeron’s AI Screener
In my own research and trading process, I’ve found Tickeron’s AI Screener invaluable for cutting through the noise. This AI-powered tool lets me scan thousands of stocks and ETFs using customizable filters on technical patterns, fundamentals, trends, volatility, and AI signals—spotting trade ideas, breakouts, and opportunities far faster than manual methods. It’s become a staple for comparing names like STE to industry peers efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
STE in downward trend: 10-day moving average crossed below 50-day moving average on September 11, 2026
The 10-day moving average for STE crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 69 cases where STE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STE as a result. In 56 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
STE moved below its 50-day moving average on September 04, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
The Aroon Indicator for STE entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STE's RSI Indicator exited the oversold zone, 22 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for STE just turned positive on September 29, 2026. Looking at past instances where STE's MACD turned positive, the stock continued to rise in 29 of 47 cases over the following month. The odds of a continued upward trend are 62%.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where STE advanced for three days, in 156 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
STE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.855) is normal, around the industry mean (10.853). P/E Ratio (25.795) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (1.760) is also within normal values, averaging (11.052). STE has a moderately high Dividend Yield (0.012) as compared to the industry average of (0.002). P/S Ratio (3.423) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. STE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of surgical and other medical supplies
Industry MedicalNursingServices
Advertisement